肠道微生态制剂联合蒙脱石散治疗儿童轮状病毒性胃肠炎60例  

Effectiveness of an Intestinal Microecological Preparation Combined with Montmorillonite Powder in the Treatment of 60 Cases of Children with Rotavirus Gastroenteritis

作　　者：张亚丽 ZHANG Yali(Ruzhou First People's Hospital,Ruzhou Henan 467500,China)

机构地区：[1]汝州市第一人民医院,河南汝州467500

出　　处：《药品评价》2023年第7期863-866,共4页Drug Evaluation

摘　　要：目的研究肠道微生态制剂联合蒙脱石散对轮状病毒性胃肠炎患儿肠道菌群及血清免疫球蛋白水平的影响。方法以2019年12月至2022年12月汝州市第一人民医院收治的120例轮状病毒性胃肠炎患儿为研究对象,采用随机数字表法分为对照组、联合组,各60例。对照组采用蒙脱石散治疗,联合组采用肠道微生态制剂(双歧杆菌四联活菌)联合蒙脱石散治疗。比较两组临床疗效,治疗前及治疗1周后肠道菌群数量(乳酸杆菌、双歧杆菌、肠球菌、大肠埃希菌),血清免疫球蛋白[免疫球蛋白A(IgA)、IgG、IgM]水平,肠道黏膜屏障功能指标[二胺氧化酶(DAO)、内毒素(EXT)、D-乳酸]水平,血清补体C3、C4水平。结果联合组临床总有效率(98.33%)高于对照组(86.67%)(P<0.05)。与治疗前相比,治疗1周后两组乳酸杆菌、双歧杆菌数量均升高,肠球菌、大肠埃希菌数量均降低,且联合组变动幅度大于对照组(P<0.05);与治疗前相比,治疗1周后两组血清IgA、IgG、IgM水平均升高,且联合组高于对照组(P<0.05);与治疗前相比,治疗1周后两组血清DAO、EXT、D-乳酸水平均降低,且联合组低于对照组(P<0.05);与治疗前相比,治疗1周后两组血清补体C3、C4水平均升高,且联合组高于对照组(P<0.05)。联合组不良反应总发生率(6.67%)与对照组(3.33%)相比,差异无统计学意义(P>0.05)。结论采用肠道微生态制剂与蒙脱石散联合治疗可有效改善轮状病毒性胃肠炎患儿免疫功能及肠黏膜屏障功能,调节肠道菌群恢复平衡,提高临床疗效,且有一定安全性。Objective To investigate the effects of intestinal microbiota preparation combined with montmorillonite powder on the microbiota and serum immunoglobulin levels in children with rotavirus gastroenteritis.Methods A total of 120 children with rotavirus gastroenteritis admitted to Ruzhou First People's Hospital from December 2019 to December 2022 were divided into control group and combined group by random number table method,with 60 cases in each group.The control group was treated with montmorillonite powder,and the combined group was treated with intestinal microbiota preparation combined with montmorillonite powder.The clinical efficacy,intestinal flora number(lactobacillus,bifidobacterium,enterococcus,escherichia coli),serum immunoglobulin(IgA,IgG,IgM)levels,intestinal mucosal barrier function indexes[diamine oxidase(DAO),endotoxin(EXT),D-lactic acid],serum complement C3 and C4 levels of the 2 groups were compared before treatment and 1 week after treatment.Results The total effective rate of the combined group(98.33%)was higher than that of the control group(86.67%)(P<0.05).Compared with before treatment,after 1 week of treatment,the number of lactobacillus and bifidobacterium in 2 groups increased,and the number of enterococcus and escherichia coli decreased,and the change range of combined group was greater than that of control group(P<0.05);serum IgA,IgG and IgM levels in 2 groups were increased after 1 week of treatment,and the combined group was higher than the control group(P<0.05);serum DAO,EXT and D-lactic acid levels in 2 groups were decreased,and the combined group was lower than the control group(P<0.05);serum complement C3 and C4 levels in 2 groups were increased after 1 week of treatment,and the combined group was higher than the control group(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the combined group(6.67%)and the control group(3.33%)(P>0.05).Conclusion The combination treatment of intestinal microbiota preparation and montmori

关 键 词：轮状病毒感染 肠道微生态制剂 蒙脱石散 胃肠炎 肠道菌群 

分 类 号：R725.1[医药卫生—儿科]